Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 147 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer (EOC) MOST POPULAR Increasing Education About Cancer Screening and Prevention in Kazakhstan May 11, 2021 Foodie Friday: Couscous Salad August 13, 2021 What Is Peripheral Neuropathy and How Can It Be Prevented or... July 14, 2020 Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included... March 23, 2021 Load more HOT NEWS New analysis estimates over 21 million UK adults will be obese... Advancing Patient Care Through Focused Innovation For AYAs with Advanced Cancer, Study Finds Serious Communication Gaps about... Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs
